Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis (NCT07441408)
An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0113 — Birmingham, Alabama
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (275 Sites)
Showing the first 25 of 275 sites.
- Local Institution - 0113 — Birmingham, Alabama
- Local Institution - 0111 — Ocala, Florida
- Local Institution - 0119 — Philadelphia, Pennsylvania
- Local Institution - 0013 — Florida, Vicente López, Buenos Aires
- Local Institution - 0014 — Mar del Plata, Buenos Aires
- Local Institution - 0007 — Quilmes, Buenos Aires
- Local Institution - 0009 — San Juan Bautista, Buenos Aires
- Local Institution - 0003 — Mar del Plata, B
- Local Institution - 0001 — Córdoba, Córdoba Province
- Local Institution - 0005 — CABA, Distrito Federal
- Local Institution - 0002 — Godoy Cruz, Mendoza Province
- Local Institution - 0011 — Mendoza, M
- Local Institution - 0015 — Rosario, S
- Local Institution - 0012 — San Miguel de Tucumán, Tucumán Province
- Local Institution - 0010 — Buenos Aires,
- Local Institution - 0004 — Buenos Aires,
- Local Institution - 0016 — CABA,
- Local Institution - 0006 — Mendoza,
- Local Institution - 0008 — Santa Fe,
- Local Institution - 0287 — Camperdown, New South Wales
- Local Institution - 0290 — Chermside, Queensland
- Local Institution - 0291 — Greenslopes, Queensland
- Local Institution - 0293 — South Brisbane, Queensland
- Local Institution - 0289 — Adelaide, South Australia
- Local Institution - 0288 — Frankston, Victoria
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Fibrosis
- Analysis of Specimens From Individuals With Pulmonary Fibrosis — Bethesda, Maryland
- Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF) — Pittsburgh, Pennsylvania
- A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis — Birmingham, Alabama
- Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis — Chicago, Illinois
- Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF) — Pittsburgh, Pennsylvania
Explore by condition: All Pulmonary Fibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.